PR90462

TIANJIN, China, July 5, 2021 /PRNewswire=KYODO JBN/ --

SINOMED, a leading international medical device company, today announced that

they have teamed up with the National University of Ireland Galway (NUI Galway)

to conduct a clinical trial for a new assessment method for stenting. The trial

will employ the newly patented, HT Supreme (R) Healing-Targeted Drug-Eluting

Stent (DES), which has the potential to break new ground in the treatment of

patients with heart disease.  

The PIONEER IV trial is a prospective, random trial that will take place in 30

hospitals across Europe, enrolling 2,540 patients and involve patients

suffering any type of coronary heart disease, including acute heart attack,

chronic complaints or vessel narrowing. Patients eligible will undergo a

non-invasive physiological vessel selection process to determine which vessel

requires stenting. All patients enrolled into the trial will use the HT Supreme

DES and be required to take one month dual-antiplatelet therapy after stenting.

Dr Jianhua Sun, PhD., chairman and chief executive officer of SINOMED, said:

“We are honored to be working with the prestigious thought leaders at NUI

Galway in searching for a better and safer strategy for treating patients. We

believe that our HT Supreme, coupled with an optimal treatment strategy can

make a big impact in bringing benefit to patients.”

Professor Timothy O’Brien, Dean of NUI Galway’s College of Medicine, Nursing

and Health Sciences, welcomed the trial. He said: “Leading this research from

Galway is consistent with the University strategy to be a global leader in

cardiovascular research and innovation and compliments the presence in the

University of CURAM, the SFI Research Centre for Medical Devices. We are

particularly happy to partner with SINOMED on this project which aligns with

the University’s Global Galway Project.”

The trial is sponsored by NUI Galway and it will be centrally coordinated by

the University’s CORRIB Research Centre for Advanced Imaging and Core

Laboratory, led by Professor Patrick W. Serruys, Established Professor of

Interventional Medicine and Innovation, and Professor William Wijns, Science

Foundation Ireland Professor of Interventional Cardiology.

More information on the PIONEER IV study is available at

www.clinicaltrials.gov, identifier: NCT04923191.

About the HT Supreme Drug-Eluting Stent:

The HT Supreme represents a novel class of stents that highlights the

importance of early, timely healing. Through patented designs and proprietary

processes, the HT Supreme is tailored to help patients accelerate their

wound-healing process and restore their naturally protective vessel function.  

About SINOMED

SINOMED is a global medical device company engaged in research, development,

production, and commercial distribution of interventional devices. We are

focused on developing breakthrough technologies to target unmet clinical needs

in the interventional treatment of coronary, neurovascular and structural heart

disease. Our mission is to expose more patients to the benefits of our medical

innovations, increasing patient longevity and quality of life. For more

information visit www.sinomed.com.

About NUI Galway

Established in 1845, NUI Galway is a bilingual university comprised of four

colleges, 19 schools, five research institutes, 19,070 students, 3,308

international students, 2,200 staff, research collaborations with 3,267

international institutions in 114 countries, 110,000 alumni, while 98% of

graduates are in employment or further study within six months.

For more information visit www.nuigalway.ie.

Photo -

https://mma.prnewswire.com/media/1556743/National_University_of_Ireland_Galway.jpg

Logo - https://mma.prnewswire.com/media/1333950/SINOMED_Logo.jpg

Contact:

Cindy Zheng

SINOMED B.V.

+31 10 307 6295

cindy.zheng@sinomed-eu.com

Source: SINOMED